Poolbeg Pharma has announced that its POLB 001 programme will form a central element of a major new UK research initiative aimed at improving the safety of cancer immunotherapies by reducing cytokine release syndrome (CRS). The programme, entitled RISE (Reducing Immune Stress from Excessive cytokine release for advanced therapies), will bring together leading clinical and scientific experts and will be supported by a grant from the MRC to the University of Manchester and The Christie NHS Foundat ....
